Top Markets
#1 MON MON +2,760.99%
#2 $1 is all you need $1 is all you need +1,328.53%
#3 PYTHIA PYTHIA +52.39%
#4 eCash eCash +39.09%
#5 PinGo PinGo +28.27%
#6 Siren Siren +24.14%
#7 Collector Crypt Collector Crypt +23.46%
#8 Janction Janction +20.22%
#9 SAFEcoin SAFEcoin +19.71%
#10 Cap Cap +14.67%
Coin of the day
MON MON
Ustawienia
Język
POLSKI
Waluta
USD
Motyw
Sensorion SA Sensorion SA

Sensorion SA

ALSEN
Pozycja w akcjach #13314
Sensorion SA, a clinical-stage biopharmaceutical company, develops drug... Sensorion SA, a clinical-stage biopharmaceutical company, develops drug candidates for the treatment of inner ear disorders in France. The company develops OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin deficiency; USHER-T1-GT, a gene therapy development program to for patients suffering from usher syndrome Type 1; and SENS-401, a drug candidate to treat sudden sensorineural hearing loss. Its pipeline also includes various products in development stage for restoring, treating, and preventing inner ear related disorders. The company has a collaboration agreement with Institut Pasteur for gene therapy program for pediatric and adult deafness; and with Sonova Holding AG to introduce genetic analysis for routine diagnosis of progressive hearing loss in adults through a combination of advanced therapeutic interventions and traditional hearing aids. Sensorion SA was founded in 2009 and is headquartered in Montpellier, France.
Cena akcji
$0.30780727
Kapitalizacja rynkowa
$94.19M
Zmiana (1 dzień)
-0.19%
Zmiana (1 rok)
-34.73%
Kraj
FR
Handel Sensorion SA (ALSEN)

Kategoria

Healthcare
EPS dla Sensorion SA (ALSEN)
EPS na dzień December 2025 TTM: $-0.11
Według najnowszych raportów finansowych i ceny akcji firmy Sensorion SA, obecny EPS (TTM) wynosi $-0.11. Na koniec roku 2023 firma miała EPS w wysokości $-0.19, spadek w porównaniu do do EPS z roku 2022, który wynosił $-0.31.
Historia EPS dla Sensorion SA od 2011 do 2026
EPS na koniec każdego roku
Rok EPS Zmień
2026 (TTM) $-0.11 14.90%
2024 $-0.10 -49.33%
2023 $-0.19 -39.60%
2022 $-0.31 43.96%
2021 $-0.22 18.28%
2020 $-0.18 -74.95%
2019 $-0.73 -41.24%
2018 $-1.24 -22.81%
2017 $-1.61 40.20%
2016 $-1.15 5.63%
2015 $-1.09 -4.53%
2014 $-1.14 65.40%
2013 $-0.69 73.77%
2012 $-0.40 103.76%
2011 $-0.19 0.00%
EPS dla podobnych firm lub konkurentów
Firma EPS Różnica w EPS Kraj
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 $4.36 -3,893.12%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $17.01 -14,904.18%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 $42.53 -37,114.80%
US
UCB SA UCB SA
UCB SA
UCB.BR
 $9.62 -8,473.19%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $26.66 -23,302.79%
NL